VantAI
Younseop Chung currently serves as Board Director and Vice President in Residence for Strategy at VantAI, where non-technical strategy development is a key focus. Since August 2019, Younseop has been a Project Leader at SK Group, engaging in corporate strategy development and investment in AI drug discovery and bio-tech across multiple roles, including positions at the Bio Investment Center. Prior experience includes consultancy at Proteovant Therapeutics, where value-up strategy development was emphasized, and new business initiatives at Kakao Corp. Younseop's career also includes venture investment at Samsung Electronics, specializing in deep-tech, and roles within the Republic of Korea Navy, focusing on defense industry cooperation and naval warfare system management. Educational credentials include a Bachelor's degree in Economics & Finance from Queen Mary University of London and participation in the Bio Chief Executive Officer Program at Seoul National University.
This person is not in any teams
VantAI
1 followers
VantAI pairs bleeding-edge machine learning techniques with deep systems biology expertise to build computational models that uncover hidden relationships between molecules, targets, and diseases. These models power a best-in-class solution that identifies and generates new molecular entities for targets of interest, repurposes existing molecules at any stage of development, uncovers accurate ADME and toxicological insights, and predicts adverse events likely to influence trial success from deep analysis of systems-based pharmacogenomics. VantAI's in silico platform specializes in modelling complex protein-protein interactions, powering the discovery of biologics and protein degraders in addition to small-molecule drugs. It has helped leading biopharma partners launch new development programs--or revitalize old ones--at a fraction of the time and cost of traditional methods.